Insmed - INSM Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 12-month price targets for Insmed's shares. Their INSM share price forecasts range from $28.00 to $53.00. On average, they anticipate the company's share price to reach $43.33 in the next twelve months. This suggests a possible upside of 154.6% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.

Insmed's stock was trading at $19.98 at the beginning of the year. Since then, INSM stock has decreased by 14.8% and is now trading at $17.02.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our INSM earnings forecast.

Insmed Incorporated (NASDAQ:INSM) issued its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.13. The biopharmaceutical company had revenue of $46.80 million for the quarter, compared to analysts' expectations of $49.23 million. Insmed had a negative trailing twelve-month return on equity of 865.02% and a negative net margin of 196.26%. Insmed's revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) EPS.

ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3X Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Russell 2000 Growth ETF (IWO) and JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.36%), T. Rowe Price Investment Management Inc. (6.18%), William Blair Investment Management LLC (2.50%), Alliancebernstein L.P. (1.92%), Geode Capital Management LLC (1.84%) and Norges Bank (0.99%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $17.02.

Insmed (NASDAQ:INSM) has a market capitalization of $2.32 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

The company employs 373 workers across the globe.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.